Central nervous effects of Exenatide i.v. vs. NaCl 0.9% on regulation of hunger and satiety in obesity and type 2 diabetes: an fMRI study. Amendment 1: increase of dosage.

Trial Profile

Central nervous effects of Exenatide i.v. vs. NaCl 0.9% on regulation of hunger and satiety in obesity and type 2 diabetes: an fMRI study. Amendment 1: increase of dosage.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Exenatide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms Neuroimaging and Obesity
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Jul 2012 Actual initiation date (13 Jan 2010) added as reported by German Clinical Trials Register.
    • 21 Apr 2012 Planned number of patients changed from 20 to 40 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top